CDC presently suggests a two-phase testing course of action for Lyme disease. Both actions are necessary and can be carried out using the very same blood sample. If this first stage is damaging, no more testing is usually recommended. Also, the immune response to borrelia is heterogeneous, and never all conditions are captured by present antibod